ITGB2 and small cell lung carcinoma: On the other hand, they also provide a plausible explanation for the resistance of SCLC to tyrosine EGFR-TKIs (including Erlotinib, Gefitinib and Afatinib, Table S7), and suggest the development of novel therapeutic strategies for SCLC combining EGFR-TKIs and ITGB2-LOF.